Virpax Pharmaceuticals reports Molecular Envelope Technology human study data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2025
0mins
Virpax Pharmaceutical and Nanomerics Collaboration: Virpax Pharmaceutical congratulated Nanomerics on the successful completion of a human study using Molecular Envelope Technology (MET), which showed no severe adverse events. Virpax utilizes MET in its products Envelta, aimed at pain management, and NobrXiol, designed for delivering cannabidiol to manage epilepsy.
SUNLIGHT Trial Overview: The SUNLIGHT trial, a Phase I clinical study involving 28 days of administration of OC134 and MET eye drops to healthy volunteers, was conducted to assess safety, side effects, and dosing. The trial commenced in December 2024 and concluded in January 2025, focusing on the effectiveness of the new treatment delivery methods.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
